Pentraxin-3 vs C-reactive Protein and Other Prognostic Biomarkers in Acute Coronary Syndrome: A Substudy of the Platelet Inhibition and Patients Outcomes (PLATO) Trial by Kontny, Frederic et al.
Pentraxin-3 vs. C-reactive protein and other prognostic biomarkers in acute coronary 
syndromes:  A substudy of the PLATelet inhibition and patients Outcomes (PLATO) trial. 
 
Frederic Kontny MD, PhD1,2, Thomas Andersen MD3, Thor Ueland PhD 4,5,6, Axel Åkerblom MD, 
PhD7,8, Tatevik Ghukasyan Lakic MSc8, Annika E Michelsen PhD4,6, Pål Aukrust MD, PhD4,5,6,9, 
Maria Bertilsson MSc8 , Richard C Becker MD10,  Anders Himmelmann MD, PhD11, Stefan K James 
MD, PhD7,8, Agneta Siegbahn MD, PhD7,12, Robert F Storey MD, DM13, Lars Wallentin MD, PhD7,8, 
for the PLATO Investigators. 
 
1Stavanger University Hospital, Department of Cardiology, Stavanger, Norway; 2Drammen Heart 
Center, Drammen, Norway. 3Stavanger University Hospital, Department of Anaesthesiology, 
Stavanger, Norway; 4Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, 
University of Oslo, Oslo, Norway; 5K.G. Jebsen Inflammatory Research Center, University of Oslo, 
Norway; 6K.G.Jebsen - Thrombosis Research and Expertise Center (TREC), University of Tromsø, 
Tromsø, Norway; 7Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, 
Sweden; 8Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden; 9Section of 
Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway; 
10Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, Academic 
Health Center, Cincinnati, OH, USA; 11AstraZeneca Research and Development, Gothenburg, 
Sweden; 12Department of Medical Sciences, Clinical Chemistry and Uppsala Clinical Research Center, 
Uppsala University, Uppsala, Sweden; 13Department of Infection, Immunity and Cardiovascular 
Disease, University of Sheffield, Sheffield, United Kingdom;  
 
Corresponding author: Frederic Kontny, MD, PhD, 12Stavanger University Hospital, Department of 
Cardiology, Gerd-Ragna Bloch Thorsens gate 8, NO-4011 Stavanger, Norway. E-mail: 




Aims: We investigated the dynamics, associations with patient characteristics, other 
biomarkers, and clinical outcomes of pentraxin 3 (PTX3) in acute coronary syndromes (ACS).  
Methods and Results: In multivariate analyses, PTX3 measured in  5154 patients randomised 
in the PLATO trial (NCT00391872) were compared with leukocytes, hs-CRP,  IL-6, cystatin C, NT-
proBNP, hs-TnT and GDF-15 concerning prediction of clinical outcome.  
PTX3 peaked earlier than hs-CRP and was more strongly correlated with NT-proBNP and hs-TnT 
than with hs-CRP. The frequency of cardiovascular (CV) death, spontaneous myocardial infarction 
(sMI) or stroke by quartiles of PTX3 at admission was 6.1%, 7.3%, 9.7% and 10.7%, respectively (p < 
0.0001). The hazard ratio (HR) per 50% increase of PTX3 was 1.13 (95% confidence interval [CI]: 
1.07-1.19), p<0.0001. This association remained significant after stepwise adjustments for leukocytes/ 
hs-CRP (1.09 [1.02-1.15]), p=0.009, IL-6 (1.07 [1.01-1.14]), p=0.026, and cystatin C (1.07 [1.00-
1.13]), p=0.044, but not after adjustment for NT-proBNP, hs-TnT and GDF-15.  Admission PTX3 was 
also associated with several of the individual endpoint components (CV death/sMI; p=0.008, CV 
death; p=0.026, and sMI; p=0.017), but not with stroke. PTX3 measured in the chronic phase (i.e. at 1 
month) was still predictive of the composite endpoint in univariate analysis (1.12 [1.04-1.20] per 50% 
increase) p=0.0024, but not after adjustment for the other biomarkers.  
Conclusion: Admission level of PTX3 is a modestly stronger predictor than hs-CRP and IL-6, 
but not than NT-proBNP or hs-TnT, concerning CV outcome in ACS. But, PTX3 is more strongly 
correlated with NT-proBNP and hs-TnT than with hs-CRP.  
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Biomarkers reflecting different facets of the underlying pathophysiological processes in 
coronary artery disease (CAD) are associated with the risk of new events both in the acute and chronic 
phase of this condition. C-reactive protein (CRP), the prototypic marker of inflammation, has been 
shown in several series to be closely linked to adverse outcome, as has interleukin-6 (IL-6), a potent 
inducer of CRP.  Other well-established biomarkers for outcome prediction reflect myocardial 
necrosis (cardiac troponin) and dysfunction (N-terminal pro b-type natriuretic peptide [NT-proBNP]), 
and impaired renal function (estimated glomerular filtration rate [eGFR] and cystatin C).  
Cardiac and inflammatory biomarkers both peak in the acute phase of myocardial infarction and are 
mainly related to infarct size and thereby to mortality and development of heart failure, whereas the 
association of biomarkers to clinical outcome including risk of reinfarction in the chronic phase may 
be more closely linked to the progression of the underlying vascular disease.   
The long pentraxin 3 (PTX3) is an evolutionarily preserved, multimeric acute phase protein 
from the same superfamily of inflammatory glycoproteins as CRP and is one of several long 
pentraxins recently identified, whereas CRP and human serum amyloid P component (SAP) are the 
two prototypic short human pentraxins.1,2 PTX3 shares homology with CRP at the C-terminal, but has 
no homology to any known protein at its N-terminal.3 Unlike CRP, PTX3 is produced at sites of 
inflammation including the vascular endothelium, and might add information on the role of 
inflammation in atherosclerotic disorders beyond that of CRP. Several earlier studies on PTX3 in 
patients with CAD were rather small and included narrow patient populations making the 
generalizability of the results difficult.  
The objectives of the current study were to investigate, in a contemporary cohort of patients 
with acute coronary syndrome (ACS), the dynamics of PTX3 release in both the acute and chronic 
phases of CAD, to assess the associations between PTX3 levels with fatal and non-fatal cardiovascular 
outcomes in both disease stages, and to compare these dynamics and associations with those of CRP, 





The PLATO (PLATelet inhibition and patient Outcomes [NCT00391872]) trial was a 
multicentre, randomised trial that enrolled 18624 patients with the whole spectrum of ACS (i.e. 
unstable angina, non-ST-segment elevation myocardial infarction [NSTEMI], and ST-segment 
elevation myocardial infarction]4. In- and exclusion criteria in the PLATO trial (identical for this 
substudy) are listed in the online supplement together with number of patients in each diagnosis 
category. All patients received optimal medical therapy, including aspirin, and were randomised to 
either clopidogrel or ticagrelor. The follow-up in the study was up to 12 months with a median of 9 
months. Details of the study design have been previously published.5 
The present substudy was part of a prespecified biomarker research project embedded in the 
extended PLATO trial program. All PLATO study patients at selected sites were invited on a 
consecutive basis to participate in this program which included venous blood sampling scheduled at 
randomisation, discharge, and after 1 and 6 months. Informed consent was obtained from all patients, 
and the trial complied with the Helsinki declaration. The research protocol was approved by the 
locally appointed ethics committees. 
 
Study endpoints 
The primary efficacy endpoint of this substudy was the composite of cardiovascular (CV) 
death, spontaneous myocardial infarction (sMI) or stroke within one year of follow-up. The individual 
components of the primary endpoint were also analysed separately. An independent, blinded clinical 
events adjudication committee assessed all efficacy and safety endpoints in the PLATO trial.4 Efficacy 
endpoint definitions are listed in the online supplement.  
 
Laboratory analyses 
Venous blood samples were drawn at randomisation, but before study drug administration, 
and within 24 hours of start of chest pain, as well as at hospital discharge and 1- and 6-month follow-
up. After centrifugation, the serum was stored in aliquots at -70ºC in a central biobank. PTX3 levels 
were measured by enzyme immunoassay (Stillwater, MN, USA) with intra- and inter-assay 
coefficients of variation 2.5% and 8.7%, respectively, and a sensitivity of  0.031 µg/L. Repeated 
analyses both after sample storage at room temperature and up to 10 freeze-thaw cycles indicated that 
PTX3 is a robust protein with little degradation, and if anything more stable than CRP (suppl. tab. 1).  




Crude event rates at 1 year by PTX3 quartiles at baseline were estimated as well as Kaplan 
Meier event rates. The associations of baseline PTX3 concentrations (ln-transformed) with the primary 
composite endpoint and its individual components were assessed both by multivariable Cox 
proportional hazards models, with the hazard based on a 50% increase in biomarker concentration as 
well as by PTX3 quartiles. Six models, with incremental addition of co-variates, were used. Model 0 
included randomised treatment only (ticagrelor or clopidogrel). Model 1 added clinical baseline risk 
factors; age, gender, body mass index (BMI), diabetes mellitus (DM), chronic kidney disease (CKD), 
hypertension, smoking status, type of ACS, and history of congestive heart failure (CHF), MI, 
percutaneous coronary intervention (PCI), coronary artery by-pass grafting (CABG), stroke or 
peripheral artery disease (PAD). Model 2 included all variables from model 1 together with 
inflammatory biomarkers (2A: leukocyte count and hs-CRP; 2B: leukocyte count, hs-CRP and IL-6). 
Model 3 included all the previous mentioned co-variates, with the addition of cystatin C. Model 4 
included hs-TnT and NT-proBNP to all variables in model 3, and model 5 contained GDF-15 in 
addition to all aforementioned variables.  
Further details to the statistical methods are given in the online supplement.  
 
RESULTS 
PTX3 IN THE ACUTE PHASE 
PTX3 levels in relation to clinical characteristics and other biomarkers 
Acute phase levels of PTX3 were available for 5154 patients with a median value (IQR) of 
1.89 ng/ml (1.22-2.97 µg/L). Baseline characteristics by PTX3 quartiles are presented in tab. 1. Age, 
female gender, diabetes, CHF, CKD, higher TIMI and GRACE risk scores, and the use of diuretics or 
proton pump inhibitors were positively correlated with PTX3 levels. Current smoking, ST-elevation 
MI, indicators of the metabolic syndrome (weight, BMI, or dyslipidaemia) and statin use were 
associated with lower PTX3 levels.  
 
Table 1: Baseline characteristics and biomarker levels according to quartiles of acute phase 
(i.e. admission) PTX3 levels. *: P-values from chi-square test (categorical variables) or 
Kruskal-Wallis test (continuous variables). 
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Demographics Age yrs median (Q1-Q3) 59 (52-67) 61 (54-69) 63 (54-71) 65 (56-73) <.0001 
Female 339 (26.3%) 377 (29.2%) 396 (30.7%) 433 (33.6%) 0.0007 
Weight kg median (Q1-Q3) 84 (74-93) 80 (72-90) 80 (70-90) 78 (68-88) <.0001 
BMI kg/m2 median (Q1-Q3) 28.3 (25.8-31.1) 27.7 (25.1-30.9) 27.4 (24.9-30.4) 27.0 (24.2-29.8) <.0001 
Risk factor Habitual smoker 551 (42.7%) 456 (35.4%) 476 (37.0%) 415 (32.2%) <.0001 
Hypertension 834 (64.7%) 865 (67.1%) 856 (66.5%) 846 (65.7%) 0.6041 
Dyslipidaemia 590 (45.8%) 545 (42.3%) 540 (41.9%) 507 (39.4%) 0.0118 
Diabetes mellitus 264 (20.5%) 289 (22.4%) 272 (21.1%) 321 (24.9%) 0.0347 
Medical history Angina pectoris 606 (47.0%) 622 (48.3%) 606 (47.0%) 566 (43.9%) 0.1537 
Myocardial infarction 251 (19.5%) 255 (19.8%) 246 (19.1%) 257 (20.0%) 0.9511 
Congestive heart failure 64 (5.0%) 59 (4.6%) 74 (5.7%) 99 (7.7%) 0.0034 
PCI 180 (14.0%) 147 (11.4%) 164 (12.7%) 146 (11.3%) 0.1349 
CABG 63 (4.9%) 68 (5.3%) 54 (4.2%) 71 (5.5%) 0.4359 
TIA 23 (1.8%) 28 (2.2%) 30 (2.3%) 32 (2.5%) 0.6530 
Non-haemorrhagic stroke 34 (2.6%) 42 (3.3%) 53 (4.1%) 48 (3.7%) 0.1936 
Peripheral arterial disease 81 (6.3%) 89 (6.9%) 86 (6.7%) 93 (7.2%) 0.8131 
Chronic renal disease 30 (2.3%) 27 (2.1%) 56 (4.3%) 67 (5.2%) <.0001 
Type of ACS ST-elevation MI 661 (51.3%) 568 (44.1%) 563 (43.7%) 569 (44.2%) 0.0001 
Risk scores TIMI risk score median (Q1-Q3) 3.0 (2.0-4.0) 4.0 (2.0-5.0) 4.0 (3.0-5.0) 4.0 (3.0-5.0) <.0001 
GRACE risk score median (Q1-Q3) 127 (113-143) 133 (116-149) 136 (120-153) 142 (124-161) <.0001 
Anti-thrombotic  
treatment in hospital 
Aspirin 1274 (98.8%) 1266 (98.2%) 1271 (98.7%) 1260 (97.8%) 0.1620 
Unfractioned heparin 673 (52.2%) 696 (54.0%) 696 (54.0%) 750 (58.2%) 0.0172 
LMW heparin 686 (53.2%) 692 (53.7%) 709 (55.0%) 696 (54.0%) 0.8167 
Fondaparinux 32 (2.5%) 19 (1.5%) 10 (0.8%) 12 (0.9%) 0.0009 
Bivalirudin 17 (1.3%) 27 (2.1%) 20 (1.6%) 12 (0.9%) 0.0982 
GP IIb/IIIa inhibitor 355 (27.5%) 311 (24.1%) 345 (26.8%) 359 (27.9%) 0.1264 
Other medication  
in hospital 
Beta-blockers 1141 (88.5%) 1123 (87.1%) 1126 (87.4%) 1095 (85.0%) 0.0618 
ACE-inhibition and/or ARB 1137 (88.2%) 1118 (86.7%) 1103 (85.6%) 1119 (86.9%) 0.2885 
Cholesterol lowering (statin) 1226 (95.1%) 1210 (93.9%) 1213 (94.2%) 1179 (91.5%) 0.0018 
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Ca-inhibitor 268 (20.8%) 275 (21.3%) 268 (20.8%) 266 (20.7%) 0.9758 
Diuretic 415 (32.2%) 448 (34.8%) 479 (37.2%) 615 (47.7%) <.0001 
Proton pump inhibitor 512 (39.7%) 522 (40.5%) 584 (45.3%) 650 (50.5%) <.0001 
Biomarkers hs-Troponin T (ng/L) median (Q1-Q3) 65.1 (20.4-226.0) 123.0 (35.6-394.0) 207.0 (61.7-623.0) 376.0 (105.0-1163) <.0001 
NT-proBNP (pmol/L) median (Q1-Q3) 205.0 (70.0-548.0) 345.0 (117.0-843.0) 461.0 (177.0-1147) 933.0 (305.0-2574) <.0001 
Cystatin C (mg/L) median (Q1-Q3) 0.77 (0.64-0.93) 0.81 (0.67-0.97) 0.83 (0.67-1.02) 0.87 (0.70-1.11) <.0001 
GDF-15 (ng/L) median (Q1-Q3) 1386 (1055-1869) 1463 (1111-1955) 1535 (1147-2140) 1871 (1308-2881) <.0001 
hs-CRP (mg/L) median (Q1-Q3) 2.7 (1.3-5.4) 3.1 (1.5-7.0) 3.6 (1.6-9.8) 6.2 (2.2-20.0) <.0001 
IL-6 (ng/L) median (Q1-Q3) 2.6 (1.7-4.3) 3.0 (1.7-5.7) 3.6 (2.1-7.3) 5.8 (2.6-12.0) <.0001 
 
Abbreviations: ACE: Angiotensin converting enzyme, ARB: Angiotensin receptor blocker, BMI: Body mass index, Ca: Calcium, CABG: Coronary artery bypass graft 
surgery, GDF-15: Growth differentiation factor 15, GP: Glycoprotein, GRACE: Global Registry of Acute Coronary Events, hs-CRP: High sensitive C-reactive protein, IL-6: 
Interleukin-6, LMW: Low molecular weight, MI: Myocardial infarction, NT-proBNP: N-terminal prohormone of brain natriuretic peptide, PCI: Percutaneous coronary 
intervention, TIA: Transitoric ischaemic attack, TIMI: Thrombolysis In Myocardial Infarction. 
 
Acute phase levels of PTX3 correlated significantly with cardiac and renal (i.e. hs-TnT and 
NT-proBNP) as well as inflammatory (hs-CRP, IL-6, and leukocytes) biomarkers (p<.0001 for all). 
Strongest correlations were seen between PTX3 and biomarkers of myocardial damage and 
dysfunction (Spearman correlation coefficient for PTX3 vs. hs-TnT: 0.33, and PTX3 vs. NT-proBNP: 
0.34), while weaker correlations were found with inflammatory biomarkers; hs-CRP: 0.24, IL-6: 0.29, 
and leukocyte count: 0.13 (suppl. tab. 2).  
To assess the strength of association (F-value) of PTX3 to the other biomarkers, a 
multivariable general linear model containing biomarkers and clinical covariates was conducted with 
PTX3 level as dependent variable. The F statistics was used for analysis of variance, representing 
explained versus unexplained variance. The highest F-value (i.e. strongest association) was seen 
between PTX3 and NT-proBNP and hs-TnT, respectively ( Fig. 1). Scatterplots for PTX3 vs. hs-TNT 
and NT-proBNP are shown in suppl. fig. 1a and b.  
In multivariable linear regression analyses including clinical characteristics only, age (p < 
0.0001), female gender (p = 0.0045), and chronic kidney disease (p = 0.0011) remained independently 
associated with higher PTX3 levels, whereas dyslipidaemia (p = 0.0013) and BMI ≥ 30 kg/m2 (p < 
0.0001) were the only factors still significantly associated with lower levels.  In fully-adjusted 
multivariable regression analyses including both baseline characteristics and other biomarkers, higher 
PTX3 levels remained independently associated with the acute phase cardiac biomarkers hs-TNT and 
NT-proBNP, and stronger so than with hs-CRP, leukocyte count and GDF-15, whereas the 
associations with IL-6 and cystatin C were no longer statistically significant (table 2).  
 
Table 2: Association of acute (i.e. admission) and chronic phase (i.e. at 1 month post-ACS) PTX3 
levels with other biomarkers in adjusted* multivariable linear regression analyses. The relative 




increase 95% CI 
P-
value 
NT-proBNP A 1.0090 1.0072 - 1.0109 <.0001 
 C 1.0060 1.0032 - 1.0089 <.0001 
hs-Troponin T A 1.0066 1.0053 - 1.0080 <.0001 
 C 1.0003 0.9961 - 1.0044 0.9065 
GDF-15 A 1.0132 1.0086 - 1.0177 <.0001 
 C 1.0138 1.0066 - 1.0210 0.0002 
Cystatin-C A 0.9945 0.9877 - 1.0014 0.1198 
 C 1.0045 0.9935 - 1.0156 0.4255 
hs-CRP A 1.0041 1.0023 - 1.0058 <.0001 
 C 1.0036 1.0009 - 1.0063 0.0098 
WBC A 1.0274 1.0206 - 1.0341 <.0001 
 C 1.0068 0.9961 - 1.0176 0.2158 
IL-6 A 1.0018 0.9990 - 1.0048 0.1958 
 C 0.9946 0.9905 - 0.9987 0.0096 
 
* Adjusted for age, gender, diabetes, CHF, type of ACS (i.e STEMI vs non-STEMI), in-hospital 
treatment approach, previous PCI/CABG/MI/PAD/NH-Stroke, chronic kidney disease, arterial 
hypertension, smoking status, dyslipidemia, BMI, and aspirin at entry.   
Abbreviations: A: Acute phase, C: Chronic phase, CABG: Coronary artery by-pass grafting, CHF: Congestive heart failure, 
GDF-15: Growth differentiation factor 15, hs-CRP: High sensitive C-reactive protein, , IL-6: Interleukin 6, MI: Myocardial 
infarction, NH: Non-haemorrhagic, NT-proBNP: N-terminal prohormone of brain natriuretic peptide, STEMI: ST-elevation 
myocardial infarction,  PAD: Peripheral artery disease, PCI: Percutaneous coronary intervention, WBC: White blood cell 
(leukocyte) count. 
Association of PTX3 with clinical outcome 
The primary composite endpoint was observed in 435 of 5154 patients (8.4%) with 193 were 
CV-deaths, 242 sMIs, and 62 strokes. The crude event rates of the primary endpoint were 6.1%, 7.3%, 
9.7% and 10.7% per quartile of PTX3, respectively (p<0.0001). Kaplan-Meier estimates for the 
primary outcome are presented in fig. 2. The acute phase PTX3 level (with HR per 50% increase of 
PTX3 as continuous variable) was significantly associated with the primary composite endpoint, HR: 
1.17 (95% CI: 1.11-1.23), p<0.0001.  
In multivariable Cox regression analyses, the acute phase PTX3 level remained significantly 
associated with the primary outcome after adjustment for randomised treatment, clinical risk factors, 
leukocyte count and hs-CRP (1.09 [1.02-1.15]), p=0.009 (model 2A). This association remained 
statistically significant also after stepwise entering of IL-6 (1.07 [1.01-1.14]), p=0.026 (model 2B), 
and cystatin C (1.07 [1.00-1.13]), p=0.044 (model 3) into the analyses. PTX3 was furthermore 
significantly associated with the following individual components of the primary endpoint after 
adjustment for leukocyte count and hs-CRP (model 2A): CV death/sMI, CV death, sMI and with CV 
death/all MI/stroke, and remained statistically significant also after entering both IL-6 and cystatin C 
into the model (model 2B and 3) (tab. 3). Figure 3 shows, however, that the associations of PTX3 
levels with the individual outcome measures were non-linear. There was no association between PTX3 
and stroke alone.  
 
Table 3: Association of acute phase (i.e. admission) PTX3 levels with the primary composite endpoint 
and its individual components. (Multivariable Cox regression analyses with HR per 50% increase of 
PTX3 as continuous variable. Stepwise adjustments for leukocytes / hs-CRP (model 2A), leukocytes / 
hs-CRP / IL-6 (model 2B), and leukocytes / hs-CRP / IL-6 / cystatin C (model 3).    
 
Outcome Leukocytes /  
hs-CRP 




Leukocytes /  
hs-CRP / IL-6 




Leukocytes /  hs-CRP /     
IL-6 / cystatin C 




       
CV death / sMI / stroke 1.09 (1.02-1.15) 0.0085 1.07 (1.01-1.14) 0.0264 1.07 (1.00-1.13) 0.0438 
CV death / sMI 1.11 (1.05-1.19) 0.0009 1.10 (1.03-1.18) 0.0042 1.09 (1.02-1.17) 0.0076 
CV death 1.16 (1.06-1.27) 0.0012 1.13 (1.03-1.24) 0.0111 1.11 (1.01-1.23) 0.0262 
sMI 1.10 (1.02-1.20) 0.0180 1.11(1.02-1.20) 0.0143 1.11 (1.02-1.20) 0.0166 
CV death / all MI / stroke 1.09 (1.03-1.16) 0.0016 1.08 (1.02-1.15) 0.0063 1.08 (1.02-1.14) 0.0103 
stroke 0.88 (0.75-1.03) 0.1124 0.88 (0.75-1.04) 0.1340 0.88 (0.75-1.03) 0.1092 
 
Abbreviations: CV: Cardiovascular, hs-CRP: High sensitive C-reactive protein, IL-6: Interleukin 6, M: Myocardial 
infarction, sMI: Spontaneous myocardial infarction. 
 
In fully-adjusted adjusted analyses (i.e. including NT-proBNP, hs-TnT and GDF-15), PTX3 was no 
longer significantly associated with the primary outcome measures or any of its individual 
components. The association with clinical outcome did not remain statistically significant when PTX3 
was applied as categorical variable (suppl. tab. 3). 
The PTX3 level at discharge was significantly lower in the clopidogrel vs. ticagrelor treatment 
group (geometric mean clopidogrel: 1.67, ticagrelor: 1.78, ratio of geometric means (95%CI): 1.07 
(1.03-1.11), p = 0.0002), whereas no difference was seen in the PTX3 levels at admission, 1 and 6 
months, respectively. No significant interaction was seen between the acute phase PTX3 levels and 
randomised treatment for the primary endpoint (suppl. fig. 2) or any of the other outcome measures 
(suppl. tab. 4). Corresponding analyses adjusted for NSTEMI vs. STEMI did not reveal any difference 
concerning outcome between these groups (suppl. tab. 5 and suppl. fig. 3). 
 
PTX3 IN THE CHRONIC PHASE 
Dynamics of PTX3 vs. CRP and IL-6 release 
 Serial PTX3 measurements during follow-up revealed an early peak at baseline with a gradual 
decrease during the acute phase and continuing through 6 months. Median PTX3 value (IQR) at entry 
was 1.89 (1.22-2.97) µg/L, at discharge 1.74 (1.13-2.65) µg/L (p<0.0001 vs. baseline, n=4584), 1 
month: 1.23 (0.79-1.86) µg/L (p<0.0001 vs. baseline, n=4259), and 6 months: 0.99 (0.61-1.49) µg/L 
(p<0.0001 vs. baseline, n=3106), respectively. When comparing the dynamics of PTX3 release with 
hs-CRP and IL-6, the very early maximum level was similar to IL-6 and more rapid than the 
maximum of hs-CRP seen several days later. The elevation of PTX3 still lasted longer than that of 
both hs-CRP and IL-6 (fig. 4). 
 
Association of PTX3 with clinical characteristics and other biomarkers 
After one month, independent positive associations remained between PTX3 levels and the 
following clinical characteristics: Female gender (p <0.0122) and dyslipidaemia (p =0.0058), whereas 
among those variables negatively correlated with PTX3 in the acute phase only current smoker 
remained significantly associated with PTX3 (p < 0.0001).   
As opposed to the acute phase, there was no longer any association of PTX3 with hs-TnT at 
this stage, but the association with NT-proBNP remained statistically significant (p < 0.0001) as did 
the associations with GDF-15 (p = 0.0002) and hs-CRP (p = 0.0098). IL-6 was now negatively 
associated with PTX3 (p = 0.0096), and no significant association was present with leukocyte count or 
cystatin C (table 2). 
 
Association of PTX3 with clinical outcome 
 Follow-up measurements at 1 month were available for 4233 patients without preceding CV 
events since their index event, of which 240 (5.7%) later suffered a primary composite endpoint. 
PTX3 was significantly associated with the composite primary outcome with HR (95%CI) per 50% 
increase: 1.12 (1.04-1.20), p = 0.0024. This association did not remain statistically significant when 
adjusted for any of the other biomarkers including (suppl. tabs. 6 and 7), a result that also applied to 
hs-CRP measured at this point in time (suppl. tab. 8). IL-6 remained, however, significantly associated 
with this outcome in models 2 and 3 applied as continuous variable (suppl. tab. 9).  
Statistical analyses concerning the predictive value of PTX3 at 6 months was not performed 
due to both the fact that a substantial number of patients were followed up for only a few weeks 
thereafter, and a low number of events of the primary outcome measure occurred after that point 
(ticagrelor: 46, clopidogrel: 41). 
   
DISCUSSION  
We found that the acute phase (i.e. admission) level of PTX3 was a significant predictor of the 
composite of CV death, sMI and stroke within 12 months, independently of  hs-CRP and IL-6, and of 
cystatin C. Furthermore, elevated PTX3 predicted increased risk for several of the individual 
components of the primary outcome. However, after adjustment for NT-proBNP and hs-TnT, with or 
without GDF-15, the association with outcome was no longer statistically significant. Our findings 
suggest that PTX3 may better reflect activation of the inflammatory pathways in ACS than hs-CRP 
and IL-6 but seems inferior to markers of myocardial damage and dysfunction in the prediction of 
clinical outcome.  
Our study is by far the largest series in the literature to investigate PTX3 concerning clinical 
outcome in a broad ACS population. To the best of our knowledge, this study is also the first to 
include IL-6, a potent inducer of CRP, and cystatin C in the analyses, and is one of very few to include 
stroke in the outcome measures. Thus, PTX3 measured in the acute phase seems to be one of the 
strongest inflammatory predictors of clinical outcome in patients with ACS. However, PTX3 
measured in the chronic phase was not predictive of clinical outcome.  
Our results are concordant with a previous study showing that PTX3, but not hs-CRP, was 
significantly associated with fatal outcome within 3 months after acute ST-elevation MI.6 Neither NT-
proBNP nor TnT was predictive of mortality in that study, but there were marked differences to our 
trial in the management strategy since more than 60% received thrombolytic therapy and PCI was 
performed in only 4.3%. In contrast, thrombolytic therapy was an exclusion criterion for enrolment in 
the PLATO trial, and PCI was performed in 61% during initial hospitalisation. Thus, in our opinion, 
the present study more correctly reflects the predictive value of PTX3 concerning outcome in a 
contemporary ACS population.  
In another study of patients admitted with suspected ACS, elevated admission levels of PTX3 
and BNP, but not hs-CRP, were independently associated with fatal outcome within 24 months.7 The 
combination of PTX3 and BNP enhanced the predictive value significantly over either biomarker 
alone. A 7-years follow-up report on this cohort revealed that PTX3 and BNP were still associated 
with late mortality, while hs-CRP and BNP were predictive of new MI.8 However, this study included 
up to 50% non-ACS patients. Furthermore, the prevalence of heart failure was much higher in the 
former study (27.4% vs 5.7%), and all-cause mortality was applied as efficacy endpoint as opposed to 
CV mortality in our study.  
Another recent study found that PTX3, BNP and GRACE-score, but not hs-CRP, was 
associated with CV mortality at 5-year follow-up after acute MI in a single centre study.9 That study 
differs markedly from ours by excluding patients with CV disease including previous MI, coronary 
revascularisation, heart or renal failure, and recent inflammatory or infectious diseases. 
 The observation that PTX3 measured at one month had no predictive value concerning CV 
outcome is in line with a substudy of a lipid lowering trial in which PTX3 was not associated with 
recurrent MI or coronary death within 5 years among stable coronary artery disease patients 
randomised to pravastatin or placebo.10  
 We found that acute phase PTX3 was more strongly correlated with hs-TnT and NT-proBNP, 
i.e. markers of myocardial necrosis and dysfunction, than with inflammatory biomarkers. To our 
knowledge, a similar finding has not been reported earlier. The mechanisms behind this remain to be 
further elucidated in new studies, but one can speculate whether this is because PTX3 may be more 
closely linked than hs-CRP to local pathophysiological processes in the vasculature and myocardium.   
An increasing body of data indicate diverse functions of PTX3 in human physiology and 
pathophysiology. Although PTX3 is upregulated in high-risk plaques in ST-elevation MI as well as in 
carotid stenosis,11, 12 and is a stronger marker than hs-CRP of endothelial dysfunction,13 PTX3/ApoE-
double-knockout mice had increased vessel wall inflammation compared with ApoE-knockout 
controls.14 Furthermore, PTX3-deficient mice showed increased area of myocardial damage after 
coronary artery ligation.15 Thus, PTX3 and CRP may represent different inflammatory processes in the 
development of atherosclerosis. CRP is induced mainly in the liver as a systemic response to an 
inflammatory stimulus, primarily IL-6, but also IL-1 and IL-17. CRP accumulates in lipid-rich plaques 
where it co-localizes with T-lymphocytes. In contrast, PTX3 is produced by different cell types 
(vascular cells and innate immune cells), although not by hepatocytes upon stimulation by IL-1β, 
TNFα, and toll-like receptor agonists, but not by IL-6. It is expressed in advanced atherosclerotic 
plaques where it co-localizes with CD163-positive macrophages. PTX3 furthermore contributes to 
thrombosis by induction of tissue factor expression in monocytes and endothelial cells, but may also 
dampen leucocyte recruitment by binding to P-selectin.       
CRP may activate the complement system through both the classical and alternative pathways by 
binding to C1q and factor H, respectively. PTX3 has been shown to modulate all three complement 
pathways including the mannose-binding lectin (MBL) pathway, resulting in both pro- and anti-
inflammatory effects. Thus, CRP clearly contributes to atherosclerosis progression, whereas PTX3 
seems to exert both pro- and anti-inflammatory actions which regulate the immune-inflammatory 
response. The complete biological roles of these two pentraxins remain, however, still to be fully 
understood16. 
 Both the results of this study and own experiences concerning the analytical performance and 
robustness of PTX3 as compared with hs-CRP, indicate that  PTX3 outperforms the latter as a 
predictor of adverse clinical outcome in ACS. PTX3 can be analysed with readily available methods at 
a cost comparable with hs-CRP. However, with strong predictors like NT-proBNP and hs-TnT, only 
further studies can more clearly define the overall role of inflammatory biomarkers in this context.     
 
Study limitations 
Although the PLATO trial encompassed the whole spectrum of ACS including unstable angina as well 
as NSTEMI and STEMI. STEMI patients were eligible only if scheduled for primary PCI. 
Furthermore, need of dialysis or oral anticoagulation as well as recent significant bleeding were all 
exclusion criteria in the trial. As ticagrelor was associated with lower mortality, a survival bias in 
favour of this treatment group may have been present. However, interaction analyses revealed no 
significant association of randomised treatment with acute phase PTX3 levels concerning clinical 
outcome. 
Conclusions 
In a large, contemporary ACS population, admission levels of PTX3 predict adverse clinical outcome 
including a composite of cardiovascular death, spontaneous MI or stroke, and the individual 
components of cardiovascular death and spontaneous MI, but not stroke alone, independently of hs-
CRP, Il-6, and cystatin C. These findings suggest that PTX3 may better reflect activation of the 
inflammatory pathways in ACS than the established prototypical inflammatory marker hs-CRP. But,  
the predictive value of PTX3 concerning clinical outcome is not sustained in analyses adjusting for 
markers of myocardial damage and dysfunction, and GDF-15.  
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Figure 1: Strength of association of acute phase (i.e. admission) PTX3 level with biomarkers included 
in the multivariable analyses.  
Figure 2: Kaplan-Meier estimated event rates of the primary outcome measures per quartile of the 
acute phase (i.e. admission) PTX3 level.  
Figure 3: Restricted cubic spline of the interaction between the acute phase (i.e. admission) level of 
PTX3 and 12-months estimated event rates of the individual outcome measures in the whole study 
population.   
Figure 4: Dynamic changes of PTX3, hs-CRP, and IL-6 from admission through 6 months follow-up. 
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